| abstract |
Provided herein are therapeutic agents having specificity for human CLPTM1L polypeptide, including therapeutic agents comprising one or more CLPTM1L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1L protein dysfunction (e.g., pathogenic production, modification, or function). |